Results for tag: "Erythropoietin Stimulating Agents"

Erythropoietin Stimulating Agents (ESAs) are a class of drugs used to treat anemia associated with chronic kidney and liver disorders. ESAs are recombinant proteins that stimulate the production of red blood cells in the body. They are used to treat anemia caused by chemotherapy, chronic kidney disease, and other conditions. ESAs are administered intravenously or subcutaneously, and can be used in combination with other treatments. ESAs are generally well-tolerated, but can cause side effects such as hypertension, thrombosis, and an increased risk of stroke. The use of ESAs is regulated by the FDA, and the dosage and duration of treatment must be carefully monitored. Some companies in the ESA market include Amgen, Johnson & Johnson, Roche, and Novartis. Show Less Read more